76 results about "Potential biomarkers" patented technology

The invention discloses a magnetic resonance imaging (MRI) based brain disease individual prediction method and a magnetic resonance imaging (MRI) based brain disease individual prediction system. The method comprises the following steps: 1: obtaining the MRI of the brain of a patient with mental diseases; 2: carrying out denoising and dimension reduction treatment on the MRI of the brain of the patient; 3: carrying out feature selection by utilizing a ReliefF algorithm; 4: adaptively obtaining a spatial brain area by using a spatial cluster analysis method; 5: removing redundant features by utilizing a correlation-based feature selection algorithm, thus obtaining an optimal feature subset; 6: carrying out multiple linear regression analysis based on the optimal feature subset to recognize potential biomarkers. The method has the beneficial effects that the embodiment of the invention integrates various machine learning methods and can rapidly and conveniently achieve quantitative and individual accurate prediction of the interest features of mental diseases, such as clinical indexes, based on various image data in different mode types, thus being beneficial to understanding the brain structures, function abnormity and potential pathogenesis of the diseases.

The invention belongs to the technical field of endogenous substance detection and discloses a GC-MS (gas chromatography-mass spectrometer)-based method for quantifying eleven types of short-chain fatty acids in intestinal contents and fecal samples. By adoption of a hydrochloric acid solution prepared from saturated salt water for acidification, high-stability ethyl acetate for extraction and N-tert-butyldimethylsilyl-N-methyl trifluoroacetamide MTBSTFA for derivatization, the eleven short-chain fatty acids in mouse intestinal contents and fecal samples are quantified by a gas chromatography-mass spectrometer. The method is high in accuracy and precision and low in detection limit, can be used for quantitative detection of eleven types of short-chain fatty acids and can meet detection requirements on determination of major short-chain fatty acids in the mouse intestinal contents and the fecal samples. Moreover, the method is conducive to analysis and comparison of metabolic disposition laws of the short-chain fatty acids under normal and enteritis conditions and observation whether changes of the short-chain fatty acids can represent dynamic conditions of enteritis or not, thereby providing significant bases for potential biomarkers under the enteritis condition.

A universal data-mining platform capable of analyzing mass spectrometry (MS) serum proteomic profiles and/or gene array data to produce biologically meaningful classification; i.e., group together biologically related specimens into clades. This platform utilizes the principles of phylogenetics, such as parsimony, to reveal susceptibility to cancer development (or other physiological or pathophysiological conditions), diagnosis and typing of cancer, identifying stages of cancer, as well as post-treatment evaluation. To place specimens into their corresponding clade(s), the invention utilizes two algorithms: a new data-mining parsing algorithm, and a publicly available phylogenetic algorithm (MIX). By outgroup comparison (i.e., using a normal set as the standard reference), the parsing algorithm identifies under and/or overexpressed gene values or in the case of sera, (i) novel or (ii) vanished MS peaks, and peaks signifying (iii) up or (iv) down regulated proteins, and scores the variations as either derived (do not exit in the outgroup set) or ancestral (exist in the outgroup set); the derived is given a score of “1”, and the ancestral a score of “0”—these are called the polarized values. Furthermore, the shared derived characters that it identifies are potential biomarkers for cancers and other conditions and their subclasses.

Disclosed herein are methods and systems for identifying one or more potential biomarkers for a clinical outcome related to administration of an agent. The method includes processing molecular profile data for a plurality of subjects where the molecular profile data includes data obtained before, during and/or after administration of an agent to the plurality of subjects. The method also includes processing clinical records data for the subjects, where the clinical records data includes clinical outcome data, integrating the processed molecular profile data and the processed clinical records data for the subjects and storing in a database as merged data, selecting two or more subsets of the merged data using one or more criteria based on the clinical records data to generate two or more selected data sets, and analyzing one or more of the selected data sets to identify one or more potential biomarkers for a clinical outcome related to administration of the agent.

Cancer patients make antibodies to tumor-derived proteins that are potential biomarkers for early detection. Twenty-eight antigens have been identified as potential biomarkers for the early detection of basal-like breast cancer (Tables 1, 2). Also, a 13-AAb classifier has been developed that differentiate patients with BLBC from healthy controls with 33% sensitivity at 98% specificity (Table 3).

Type 1 diabetes (T1D) patients make antibodies to self-proteins that are potential biomarkers for early detection and risk prediction. We have identified seventeen antigens as biomarkers for early diagnosis and risk prediction of T1D, including the antigens MLH1, MTIF3, PPIL2, NUP50, TOX4, FIGN, C9orf142, ZNF280D, HES1, QRFPR, CTRC, SNX6, SYTL4, ELA2A, IGRP, PAX6, and HMGN3.

A cell response assay for cancer is provided. In the assay, the levels of a cancer cell type biomarker, a chemo resistance biomarker and a metastatic potential biomarker are simultaneously measured in a biological sample.

Biomarkers associated with preeclampsia were identified. Nine proteins were identified as being differentially regulated between the control and the under 28-weeks preeclamptic samples. Similarly three proteins were identified as being differentially regulated between the control and the over 28-weeks preeclamptic samples. These 12 proteins can be used as potential biomarkers in the diagnosing andprognosing of preeclampsia.

A method for the separation of particles of different densities using a step-wise gradient density extraction method as described herein where a sample is suspended in a liquid volume of an extracting medium of specific density and the particles that have a density less than or equal to that of the extracting medium of specific density can be recovered from a horizonatally rotatable hollow disk or a removable receptacle within a horizontally rotatable hollow disk designed for such purposes while the particles that have a density greater than the extracting medium of specific density form a deposit which can be cycled through the extraction process in an iterative fashion by varying the density of the extracting medium allowing the recovery of discrete particles of differing densities from a test sample. Also disclosed herein is the use of the above method as part of a separate method or system to identify a ratio of biomarkers from different fractions of a sample homogenate or lysate which is useful in the evaluation of potential biomarkers, and for the intraoperative pathological diagnosis of positive margins of cancer and other diseases.

The invention relates to the biomedicine field, and specifically relates to a method for screening potential biomarkers of gastric cancer based on weighted gene co-expression network analysis, and application thereof. The method for screening potential biomarkers of gastric cancer adopts weighted gene co-expression network analysis (WGCNA) and KEGG pathway and GO enrichment analysis, and other analysis methods. Weighted Gene Co-Expression Network Analysis (WGCNA) is an efficient and comprehensive method for high-dimensional data analysis, and the accuracy and validity in analyzing gene chip data of the WGCNA has been confirmed. The potential biomarker screened by the method of the invention is FERMT2. The method for screening potential biomarkers of gastric cancer based on weighted gene co-expression network analysis provides a new direction for the diagnosis, treatment and prognosis of gastric cancer, and promotes the development of individualized treatment.

LY6K is identified herein as a potential biomarker useful for the diagnosis of cancer, such as lung and esophageal cancers, as well as for the prognosis of patients with these diseases. As discussed in detail herein, LY6K is specifically over-expressed in most lung and esophageal cancer tissues examined, and is elevated in the sera of a large proportion of patients with these tumors. Accordingly, LY6K may be used in combination with other tumor markers to significantly improve the sensitivity of cancer diagnosis. LY6K may be used in the treatment of ESCC cells, as demonstrated by the fact that small interfering RNAs (siRNAs) of LY6K suppressed growth of the cancer cells. Moreover, the LY6K molecule is also a likely candidate for development of novel therapeutic approaches, such as antibody therapy.

The present invention discloses application of circular RNA FOCAD (circ-FOCAD) as a new potential diagnostic biomarker and therapeutic target for gastric cancer and colorectal cancer. The Circ-FOCAD (hsa_circ_0008678|chr9:20923658-20933102+|FOCAD) is formed by reverse splicing of No.24-27 exons of a FOCAD gene with 555 bases. The invention prepares qRT-PCR primers of the circ-FOCAD and a small interfering RNA (siRNA) which interferes with the circ-FOCAD in vitro. Compared with normal controls, the circ-FOCAD is significantly up-regulated in both tumor and plasma samples from patients with gastric cancer and colorectal cancer. In vitro experiments show that the circ-FOCAD plays a role in cancer-promoting genes in gastric cancer and colorectal cancer cells. The results of the present study indicate that the circ-FOCAD is a novel potential biomarker and therapeutic target for gastric cancer and colorectal cancer.

The invention discloses a specific autoantigen EIF2C1 of primary biliary cirrhosis (PBC). According to the specific autoantigen of PBC and the application thereof, six novel autoantigens of PBC are obtained through screening; during the detection on the blood serum of a PBC patient, the positive rate of each autoantigen reaches over 15%, so that the new-found autoantigens are potential biomarkers which are used for accurately diagnosing PBC through distinguishing other autoimmune diseases.

The present invention relates to a method for the purification, concentration and identification of glycosylphosphatidylinositol anchored proteins (GPI-APs) from a biological sample (cells, tissues and/or blood/serum) in a patient or subject, including a human patient or subject. A new method to separate GPI-anchored glycoproteins, a class of glycoproteins found in all animal cells and fluids including serum, from other glycoproteins and proteins for the purpose of identifying potential biomarkers for various diseases, including cancer, especially breast cancer, vaginal cancer, endometrial cancer, uterine cancer, cervical cancer, pancreatic cancer and prostate cancer. The method uses the alpha-toxin from Clostridium septicum to separate GPI-anchored glycoproteins for identification and optionally quantification. The GPI-APs so obtained may be used to raise antibodies for inclusion in an immunosorbent assay for the diagnosis or the monitoring of therapy of cancer in a patient.

The invention belongs to the field of biological diagnosis and medicine, and particularly relates to an application of a chemotactic factor CCL8 in preparation of a dermatomyositis condition and prognosis evaluation reagent. According to the invention, a patient plasma specimen for definite diagnosis of dermatomyositis is used as a research object; protein chip detection is carried out; a sample is expanded; a protein chip result is verified by an ELISA method; by combining biochemical indexes and clinical manifestation judgment correlation of patients, it is proved that the blood plasma CCL8level of dermatomyositis patients is remarkably higher than that of healthy people, the expression level of the blood plasma CCL8 is related to the illness state and prognosis of the patients, the blood plasma CCL8 level of dermatomyositis patients effective in treatment is remarkably reduced, and CCL8 can aggravate pulmonary lesions of interstitial pneumonia mice. Therefore, the CCL8 can be usedas a potential biomarker to be applied to a reagent for evaluating the illness state and prognosis of dermatomyositis patients, experimental data and theoretical basis are provided for the applicationof the CCL8 to the illness state and prognosis evaluation of the dermatomyositis patients, and the invention further provides a corresponding kit for evaluating the illness state and prognosis of thedermatomyositis patients.